Table of Contents
Table of Contents
List of Tables
List of Figures
Benitec Biopharma Limited Snapshot
Benitec Biopharma Limited Overview
Key Information
Key Facts
Benitec Biopharma Limited - Research and Development Overview
Key Therapeutic Areas
Benitec Biopharma Limited - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Benitec Biopharma Limited - Pipeline Products Glance
Benitec Biopharma Limited - Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Benitec Biopharma Limited - Drug Profiles
ddRNAi Program For Cancer-Associated Pain
Product Description
Mechanism of Action
R&D Progress
ddRNAi Program For Hepatitis B
Product Description
Mechanism of Action
R&D Progress
ddRNAi Program For Oculopharyngeal Muscular Dystrophy
Product Description
Mechanism of Action
R&D Progress
Drug-Resistant Lung Cancer Program
Product Description
Mechanism of Action
R&D Progress
TT-033
Product Description
Mechanism of Action
R&D Progress
TT-034
Product Description
Mechanism of Action
R&D Progress
Benitec Biopharma Limited - Pipeline Products by Route of Administration
Benitec Biopharma Limited - Pipeline Products By Mechanism of Action
Benitec Biopharma Limited - Recent Pipeline Updates
Benitec Biopharma Limited - Company Statement
Benitec Biopharma Limited - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Benitec Biopharma Limited, Recent Developments
Benitec Biopharma Limited- Press Release
Dec 18, 2012: Benitec Appoints Synteract For Phase I/IIa Clinical Trial Of TT-034 In Hepatitis C
Dec 03, 2012: Benitec Biopharma's Muscular Dystrophy Program Demonstrates Significant Gene Silencing
Nov 13, 2012: Benitec Biopharma's Tribetarna Demonstrates High Delivery And Significant Gene-Silencing In Lung Cancer Program
Financial Deals Landscape
Benitec Biopharma Limited, Deals Summary
Benitec Biopharma Limited, Pharmaceuticals & Healthcare, Deal Details
Partnerships
Benitec Biopharma Enters Into An Agreement With Stanford University
Benitec Enters Into Agreement With Children's Cancer Institute Australia for Medical Research
Benitec Enters Into Co-Development Agreement With Biomics Biotechnologies
Licensing Agreements
Benitec Amends RNAi Licensing Agreement With CSIRO
uniQure Enters Into Licensing Agreement With Benitec Biopharma For RNA Interference Technology
Benitec Biopharma Enters Into Licenising Agreement With uniQure
Benitec Biopharma Enters Into Licensing Agreement With Genable Technologies
Benitec Enters Into Licensing Agreement With Calimmune For ddRNAi Technology
Benitec Obtains Rights To T cell HIV Therapeutic
Benitec Enters Into Licensing Agreement With City of Hope
Benitec Enters Into Licensing Agreement With Tacere Therapeutics
Equity Offering
Benitec Completes Rights Issue Of $8.45 Million
Benitec Completes Rights Issue Of $0.7 Million
Benitec Completes Private Placement Of $1.36 Million
Benitec Completes Right Offering Of $4.57 Milion
Debt Offering
Benitec Raises $0.5 Million In Private Placement Of Convertible Notes.
Acquisition
Benitec Biopharma Completes Acquisition Of Tacere Therapeutics For Up To $1.2 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Benitec Biopharma Limited, Key Information
Benitec Biopharma Limited, Key Facts
Benitec Biopharma Limited - Pipeline by Indication, 2012
Benitec Biopharma Limited - Pipeline by Stage of Development, 2012
Benitec Biopharma Limited - Monotherapy Products in Pipeline, 2012
Benitec Biopharma Limited - Pre-Clinical, 2012
Benitec Biopharma Limited - Discovery, 2012
Benitec Biopharma Limited - Pipeline By Route of Administration, 2012
Benitec Biopharma Limited - Pipeline Products By Mechanism of Action, 2012
Benitec Biopharma Limited - Recent Pipeline Updates, 2012
Benitec Biopharma Limited, Other Locations
Benitec Biopharma Limited, Deals Summary
Benitec Biopharma Enters Into An Agreement With Stanford University
Benitec Enters Into Agreement With Children's Cancer Institute Australia for Medical Research
Benitec Enters Into Co-Development Agreement With Biomics Biotechnologies
Benitec Amends RNAi Licensing Agreement With CSIRO
uniQure Enters Into Licensing Agreement With Benitec Biopharma For RNA Interference Technology
Benitec Biopharma Enters Into Licenising Agreement With uniQure
Benitec Biopharma Enters Into Licensing Agreement With Genable Technologies
Benitec Enters Into Licensing Agreement With Calimmune For ddRNAi Technology
Benitec Obtains Rights To T cell HIV Therapeutic
Benitec Enters Into Licensing Agreement With City of Hope
Benitec Enters Into Licensing Agreement With Tacere Therapeutics
Benitec Completes Rights Issue Of $8.45 Million
Benitec Completes Rights Issue Of $0.7 Million
Benitec Completes Private Placement Of $1.36 Million
Benitec Completes Right Offering Of $4.57 Milion
Benitec Raises $0.5 Million In Private Placement Of Convertible Notes.
Benitec Biopharma Completes Acquisition Of Tacere Therapeutics For Up To $1.2 Million

List of Figures
Benitec Biopharma Limited - Pipeline by Indication, 2012
Benitec Biopharma Limited - Pipeline by Stage of Development, 2012
Benitec Biopharma Limited - Monotherapy Products in Pipeline, 2012
Benitec Biopharma Limited - Pipeline By Route of Administration, 2012
Benitec Biopharma Limited - Pipeline Products By Mechanism of Action, 2012

Click here to open the POPUP